Arvinas Holding Company ((ARVN)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Arvinas Holding Company is conducting a Phase 1/2 clinical trial titled A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors. The study aims to assess the safety and potential anti-tumor activity of ARV-806, an investigational drug, in adults with advanced cancer featuring the KRAS G12D mutation. This research is significant as it explores a novel treatment avenue for a challenging mutation in solid tumors.
Intervention/Treatment: The study tests ARV-806, a drug administered through intravenous infusion. It is designed to degrade a specific mutated protein in tumors, potentially inhibiting tumor growth.
Study Design: This interventional study is non-randomized and follows a sequential model. It is open-label, meaning both participants and researchers know the treatment being administered. The primary purpose is treatment-focused, with no masking involved.
Study Timeline: The study began on June 9, 2025, with the latest update submitted on August 6, 2025. These dates mark the study’s initiation and recent progress, indicating active recruitment and ongoing research efforts.
Market Implications: The progress of this study could influence Arvinas Holding Company’s stock performance positively, as successful outcomes may enhance investor confidence. The study’s focus on a specific mutation also positions Arvinas competitively within the oncology sector, potentially impacting industry dynamics.
The study is currently recruiting, with further details available on the ClinicalTrials portal.